文献速递烧伤创面修复

电纺生物膜用于烧伤创面安全且不降低皮肤移植成活率:一项随机对照临床试验

Use of an electrospun bioveil is safe and does not decrease skin graft take on burn wounds: A randomised, controlled clinical trial.
PubMed 文献 · Burns · 2025-02-18

该双盲随机对照试验纳入26例需手术的深部烧伤成人患者,每例患者自身对照,随访12个月,评估在自体刃厚皮片与创面床之间放置电纺聚乳酸-羟基乙酸共聚物(PLGA)生物膜SKINHEALTEX PLGA的安全性。结果显示生物膜耐受良好,无相关不良事件,移植成活率与瘢痕质量在对照组与干预组间无统计学显著差异。

要点

  • SKINHEALTEX PLGA生物膜在26例烧伤患者中耐受良好,未观察到相关不良事件。
  • 对照组与干预组的刃厚皮片移植成活率及后续瘢痕质量无统计学显著差异。
  • SKINHEALTEX PLGA可作为自体皮片与清创后烧伤创面床之间的界面安全应用,不降低移植成活率。

核心结论

  • SKINHEALTEX PLGA是一种生物相容且安全的产品,可作为自体皮片与清创后烧伤创面床之间的界面应用,且不降低移植成活率。
  • 这是首个在烧伤自体皮肤移植治疗中研究电纺生物材料应用的临床试验。
  • 需要进一步研究评估SKINHEALTEX PLGA对烧伤创面的价值及其作为增强皮肤再生分子给药途径的潜力。

研究设计与样本

  • 双盲随机对照临床试验,纳入需手术治疗的深部烧伤成人患者,研究期为4年(2018年11月至2022年9月)。
  • 每例患者作为自身对照,随访12个月。
  • 对照区域仅应用刃厚自体皮片,治疗区域在自体皮片与创面床之间置入SKINHEALTEX PLGA。
  • 共招募26例患者。

主要发现

  • SKINHEALTEX PLGA在26例招募患者中耐受良好。
  • 未观察到与SKINHEALTEX PLGA相关的不良事件。
  • 对照组(仅刃厚自体皮片)与自体皮片加SKINHEALTEX PLGA组在刃厚自体皮片成活率及后续瘢痕质量方面均无统计学显著差异。

局限性

  • 需要进一步研究评估SKINHEALTEX PLGA对烧伤创面的价值及其作为增强皮肤再生分子给药途径的潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Split-thickness skin autografts are the gold standard for surgical treatment of burns. In preclinical studies, the use of SKINHEALTEX PLGA, an electrospun poly(lactic-co-glycolide) acid (PLGA) bioveil, placed between autografts and their bed has shown potential to stimulate dermal regeneration, increase graft take and improve scar quality. These properties have not yet been evaluated in human clinical trials. OBJECTIVE: The primary goal of this study was to evaluate tolerability and safety of SKINHEALTEX PLGA on human tissues, specifically, split-thickness skin autografts and wound beds of debrided burns. MATERIALS AND METHODS: A double-blind randomised controlled clinical trial was conducted with adult patients with deep burns requiring surgical treatment, for 4 years (November 2018 to September 2022). Each patient acted as their own control, and they were followed for 12 months. In the control area a skin autograft was applied, while in the treatment area SKINHEALTEX PLGA was interposed between the autograft and the bed. The outcome variables were incidence of adverse events, the percentage of graft take (evaluated clinically), and Vancouver Scar Scale and Patient and Observer Scar Assesment Scale scores. RESULTS: The bioveil was well tolerated in the 26 patients that were recruited. No adverse events related to SKINHEALTEX PLGA were observed. No statistically significant differences were observed in split-thickness skin autograft take and subsequent scar quality between the control group (split-thickness skin autografts alone) and the autograft and SKINHEALTEX PLGA group. CONCLUSION: This is the first clinical trial investigating the application of an electrospun biomaterial in the treatment of burns using skin autografts. SKINHEALTEX PLGA is a biocompatible and safe product that can be applied as an interface between autografts and the debrided bed of a burn without reducing graft take. Further research is needed to assess the value of SKINHEALTEX PLGA for burn wounds and its potential as an administration route of molecules than enhance dermal regeneration in burn patients.

来源:Burns,查看原文。版权归原作者所有。

引用

  1. Pérez-Del-Caz MD, Vanaclocha N, Sepúlveda Sanchis P, et al. Use of an electrospun bioveil is safe and does not decrease skin graft take on burn wounds: A randomised, controlled clinical trial. Burns. 2025. PMID: 40014884. doi:10.1016/j.burns.2025.107427

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。